Synapse - Genitourinary Oncology Service

Results (5696)

Association of bone scan index (BSI) with prognostic biomarkers and survival in men with metastatic castration-resistant prostate cancer (mCRPC) enrolled in a prospective randomized controlled trial of tasquinimod

Meeting Abstract

Armstrong, A. J.; Kaboteh, R.; Carducci, M. A.; Damber, J. E.; Stadler, W. M.; Mats, H.; Edenbrandt, L.; Forsberg, G.; Nordle, O.; Pili, R.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Phase II randomized study of dalantercept in combination with axitinib compared to axitinib alone as second-line treatment in patients with metastatic renal cell carcinoma

Meeting Abstract

Atkins, M. B.; Bhatt, R. S.; Voss, M. H.; Rini, B. I.; Jonasch, E.; Plimack, E. R.; Alter, R.; Barger, R.; Wilson, D.; McClure, T.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

ERG rearrangements and association with clinical outcome in patients (pts) receiving abiraterone acetate (AA): Results from the COU-AA-302 study in chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Attard, G.; De Bono, J. S.; Li, W.; Molina, A.; Griffin, T. W.; Kheoh, T. S.; Ricci, D. S.; Zelinsky, K.; Rathkopf, D. E.; Scher, H. I.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Evaluating 18F-16B-fluoro-5α-dihydrotestosterone (FDHT) and FDG-PET as a measure of disease progression in metastatic castration resistant prostate cancer (mCRPC)

Meeting Abstract

Autio, K. A.; Fox, J. J.; Schneider, C. W.; Schöder, H.; Humm, J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; Haupt, E. C.; Larson, S. M.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Prostate-specific mRNA detection in whole blood as an analytically validated prognostic biomarker for patients with castration-resistant prostate cancer (CRPC)

Meeting Abstract

Anand, A.; Danila, D. C.; Heller, G.; Herkal, A.; Patel, C.; Khanin, R.; Schultz, N.; Lilja, H.; Fleisher, M.; Scher, H. I.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Amin, A.; Ernstoff, M. S.; Infante, J. R.; Heng, D. Y. C.; Rini, B. I.; Plimack, E. R.; McDermott, D. F.; Kollmannsberger, C. K.; Reaume, M. N.; Spratlin, J. L.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to cisplatin and poly (ADP-ribose) polymerase inhibition

Meeting Abstract

Cavallo, F.; Graziani, G.; Antinozzi, C.; Feldman, D. R.; Houldsworth, J.; Bosl, G. J.; Chaganti, R. S. K.; Moynahan, M. E.; Jasin, M.; Barchi, M.
Cancer Research (2013)

Fulltext@MSK | Save

Molecular biomarkers for patients with castration-resistant prostate cancer: Validating assays predictive of tumor response

Book Section

Danila, D. C.; Scher, H. I.
In Goodsaid, F.; Mattes, W. B. (Eds.) The Path from Biomarker Discovery to Regulatory Qualification (2013)

Fulltext@MSK | Save

Phase II trial of MEK inhibitor selumetinib (AZD6244) in patients with BRAFV600E/K- or NRAS-mutated melanoma

Meeting Abstract

Catalanotti, F.; Solit, D. B.; Pulitzer, M. P.; Berger, M. F.; Scott, S. N.; Iyriboz, T.; Lacouture, M. E.; Panageas, K. S.; Wolchok, J. D.; Carvajal, R. D.; more...
Cancer Research (2013)

Fulltext@MSK | Save

Delineating genomic heterogeneity in paired primary and metastatic colorectal cancer by massively parallel sequencing

Meeting Abstract

Brannon, A. R.; Vakiani, E.; Scott, S. N.; Sylvester, B.; Kania, K.; Viale, A.; Kemeny, N.; Weiser, M.; Solit, D. B.; Berger, M. F.
Cancer Research (2013)

Fulltext@MSK | Save